Experts go beyond the surface in 20/20 Pharma's Molecular Imaging podcast now live

Top Quote Go beyond the surface of Molecular Imaging with this discussion hosted by Pfizer's Tim McCarthy. Together with Carestream's Seth Gammon and Patricia Cole from Medpace Reference Laboratories, Tim explores what we can expect from this critical field. End Quote
  • New York, NY (1888PressRelease) July 21, 2011 - Industry experts go head to head in 20/20 Pharma's 'Insight into the application of Molecular Imaging to Drug Development' podcast discussion. This discussion takes listeners beyond the surface of Molecular Imaging. The podcast is available to download free at:

    The podcast is moderated by Tim McCarthy, Head of Clinical Imaging, Diagnostics & Quantitative Measurements in Pharmatx Precision Medicine at Pfizer, who is joined by two industry experts: Seth Gammon of Carestream and Patricia Cole of Medpace Reference Laboratories.

    The podcast is an insightful analysis of Molecular Imaging and includes comments on:
    - Opportunities in molecular imaging and drug development today
    - Questions about the need for imaging in drug development
    - Screening of compounds to identify a high through approach
    - The interaction between diagnostic companies, core labs and Pharma
    - Innovation and identification of new targets
    - Availability for pre-clinical imaging

    In the podcast Patricia Cole said: "Molecular Imaging really provides the opportunity to give information about certain aspects of the questions that need to be asked in drug development. One is being able to understand if a drug is getting to its target, whether its interacting with its target and what the downstream effects of that target interaction are in terms of biological effects."

    Tim McCarthy also commented: "One of the two big challenges that I see in drug development today are making sure the targets we select to develop drugs against are relevant, and we have to really understand the biology.

    "So using tools that help us understand pre-clinical biology a little more and starting to link that to some of our outcomes, genetic data and human biology, and having tools that really help us map out pathways in the clinic prior to entering into development to be sure that the target we selected is relevant."

    For more information and topical pharmaceutical related podcasts visit

    About 20/20 Pharma
    20/20 Pharma is a product of IMI Publishing Ltd, dedicated to offering its clients and partners a unique opportunity to not only advertise the capabilities of their companies, but also showcase their technology or services through in-depth educational pieces and targeted online events.
    Dedicated to being a trusted and authoritative resource within top pharmaceutical companies, as well as small, specialty and biotech businesses, 20/20 Pharma bridges the gap between the industry's top issues and the solutions that top-tier vendors can provide.

    Contact details
    Pinar Gencturk
    Managing Editor, 20/20 Pharma
    +44 207 148 5152 | pgencturk ( @ ) imipublishing dot com

  • FB Icon Twitter Icon In-Icon
Contact Information